Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants

Haematologica

Volumn 98, Issue 6, 2013, Pages 937-944

  Driessen, Emma M C ^a   van Roon, Eddy H J ^a   Spijkers Hagelstein, Jill A P ^a   Schneider, Pauline ^a   de Lorenzo, Paola ^b   Valsecchi, Maria Grazia ^b   Pieters, Rob ^a   Stam, Ronald W ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DEXAMETHASONE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; PREDNISONE; TRANSCRIPTION FACTOR HOXA9;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; INFANT; LEUKOCYTE COUNT; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

AGE OF ONSET; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE REARRANGEMENT; GENES, RAS; HOMEODOMAIN PROTEINS; HUMANS; INFANT; MUTATION; MUTATION RATE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TRANSLOCATION, GENETIC;

EID: 84878433750     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067983     Document Type: Article

References (36)

1. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia. 1996;10(2): 372-7.
2. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370(9583):240-50.
3. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108(2):669-77.
4. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLLAF4 leukemias. Cancer Cell. 2008;14(5):355-68.
5. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene. 2006; 25(22):3093-103.
6. Greaves M. In utero origins of childhood leukaemia. Early Hum Dev. 2005;81(1):123-9.
7. van der Linden MH, Valsecchi MG, De Lorenzo P, Moricke A, Janka G, Leblanc TM, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009;114(18):3764-8.
8. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4. MLL fusion protein is capable of inducing ALL in mice without requirement of MLL. AF4. Blood. 2010;115(17):3570-9.
9. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, et al. Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia. 2011;25:888-91.
10. Ng MH, Ng RK, Kong CT, Jin DY, Chan LC. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. Exp Hematol. 2010;38(6):481-8.
11. Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer. 2006;106(4): 950-6.
12. Mahgoub N, Parker RI, Hosler MR, Close P, Winick NJ, Masterson M, et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer. 1998;21(3):270-5.
13. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113(11):2375-85.
14. Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood. 2010;115(14):2835-44.
15. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 in primary MLL-generearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-90.
16. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63(15): 4561-7.
17. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4): 1209-17.
18. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76(11):2327-36.
19. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10.
20. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, Camitta BM, Loonen AH, van Wering ER, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia. 2004;18(3):521-9.
21. Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2007;110(7): 2774-5.
22. Bar-Eli M, Ahuja H, Foti A, Cline MJ. N-RAS mutations in T-cell acute lymphocytic leukaemia: analysis by direct sequencing detects a novel mutation. Br J Haematol. 1989;72(1):36-9.
23. Bos JL, Verlaan-de Vries M, van der Eb AJ, Janssen JW, Delwel R, Lowenberg B, et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 1987;69(4):1237-41.
24. Cogswell PC, Morgan R, Dunn M, Neubauer A, Nelson P, Poland-Johnston NK, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood. 1989;74(8):2629-33.
25. Janssen JW, Steenvoorden AC, Lyons J, Anger B, Bohlke JU, Bos JL, et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA. 1987;84(24):9228-32.
26. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the Nras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83(8):2248-54.
27. Needleman SW, Kraus MH, Srivastava SK, Levine PH, Aaronson SA. High frequency of N-ras activation in acute myelogenous leukemia. Blood. 1986;67(3):753-7.
28. Rodenhuis S, Bos JL, Slater RM, Behrendt H, van 't Veer M, Smets LA. Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood. 1986;67(6):1698-704.
29. Lubbert M, Mirro J Jr., Miller CW, Kahan J, Isaac G, Kitchingman G, et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood. 1990;75(5):1163-9.
30. Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L, et al. RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia. 2005;19(3): 415-9.
31. Yokota S, Nakao M, Horiike S, Seriu T, Iwai T, Kaneko H, et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol. 1998;67(4):379-87.
32. Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68(16):6803-9.
33. Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, et al. A phase I clinicalpharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011;17(5):1140-6.
34. Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma. 2010;51(2):252-60.
35. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856-62.
36. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62-8.